Biotech ‘pH Pharma’ led by alumni from Genentech and Hanmi

 To be a global healthcare company based both in Korea and U.S. through a shortening period of new drug development is pH Pharma’s goal. Hitnews went through pH Pharma from the date of foundation to the current.(For more information, please refer to the link below) http://www.hitnews.co.kr/news/articleView.html?idxno=8045

pH Pharma getting attention for its ‘license out’ during Pre-IPO

PH Pharma, which develops a treatment for glaucoma and non-alcoholic steatohepatitis (NASH), is conducting a pre-IPO (attracting funds before listing) worth 15 billion won. It is a form of large-scale purchase of new stocks (including preferred stocks) by domestic securities companies and management companies. The final goal is to be...

‘pH Pharma’s Global Strategy’. The reason why licensing-in of German and Belgian new drug candidates

Hoyoung Huh, CEO, who has experience in IPO, M&A in global biotech, founded pH Pharma in 2015..licensing-in of new drug candidates from around the world, development within short-term and technology transfer strategy..phase 2b for glaucoma treatment completed and phase 1b for Non-alcoholic steatohepatitis treatment progressed(For more information, please refer to...